David Veitch has been named president of Savient Europe, effective January 16, 2012. Mr. Veitch has extensive commercial knowledge of the EU across marketing, sales, market access and general management. Mr. Veitch will report directly to John H. Johnson, chief executive officer and president of parent company Savient Pharmaceuticals. He will be responsible for establishing, building and leading the company’s European regional organization to launch and drive the future growth of gout treatment Krystexxa. Savient submitted its European MAA in May, and anticipates approval in 2H12.
Mr. Veitch joins the company with more than 24 years of pharmaceutical industry experience at Bristol-Myers Squibb and SmithKline Beecham Pharmaceuticals, and has extensive knowledge across many therapy areas including: oncology, virology, CV-Metabolism, CNS and Immunology. Most recently he served as senior vice president of European Marketing & Brand Commercialization at BMS, where he was responsible the brand commercial organization for Europe across all disease areas.
“I am pleased to welcome David to the Savient team as head of our European operations,” said Mr. Johnson. “David has spent more than 20 years in critical pharmaceutical leadership positions within the European markets and has a track record of successfully launching specialty products in Europe. David will be a critical member of our team as we launch Krystexxa in Europe and achieve our goal of bringing relief to patients suffering from refractory chronic gout in Europe, where there are currently no EMA approved treatments for refractory chronic gout available.”